IZON designs and manufactures precision instrumentation for nano- and micro-scaled particle analysis.
Accelerate to discover
Related topics
Recent publication of in-vivo two-photon intravital imaging study targeting mouse kidney
May 22, 2023
In vivo longitudinal 920 nm two-photon intravital kidney imaging of a dynamic 2,8-DHA crystal
formation and...
Webinar: Multimodal tissue imaging and machine learning to advance precision medicine
May 17, 2023
Join us for this webinar to learn how the Orion spatial biology imaging platform was used to identify prognostic...
May 5, 2023
Decision to improve the output in a lab is always taken based on knowledge and workflow needs. But final decision to...
Real-Time and Quantitative Analysis of Macrophage Phagocytosis with RTCA eSight
May 4, 2023
The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance...
A deep learning and Monte Carlo based framework for bioluminescence imaging center Maastro
Apr 20, 2023
"In this paper,we developed a framework using deep learning for bioluminescence-based targeting for GBM animal...
Gentle sorting of microbial cells and sub-micron particles using WOLF sorter
Apr 18, 2023
While most modern applications of flow cytometry may focus on cells of eukaryotic origin, the first flow analyzers were...
SPECT imaging properties of the CdTe-Timepix3 detector used in a new prototype
Apr 5, 2023
SPECT (Single Photon Emission Computed Tomography imaging) is one of the most important and widely used methods for the...
Feb 23, 2016
InnoMedica, a Swiss nanomedicine company led by Dr. Peter Halbherr, is working towards developing a new nanocarrier platform to transport anti-cancer drugs directly to tumours, thereby avoiding the toxic effect of the drug on healthy cells. The platform will deliver existing active agents, initially Doxorubicin, encapsulated in liposomes.
The use of Doxorubicin in liposomes is well established and now off patent, being originally released as Doxil. InnoMedica’s innovative step is to attach glycans to the surface of the liposomes. Glycans are polymers of carbohydrates, also known as polysaccharides. As an imitation of the detection system of inflammation sites of the immune system, the patented glycan based targeting quickly brings the drug to the cancer site - resulting in a better efficacy, lower dosage and less side effects.
The team at InnoMedica is developing the targeting platform with a first application called Talidox (Targeted Liposomal Doxorubicin). With the release of this drug, InnoMedica aims to improve cancer treatment of many cancer patients receiving chemotherapy. Talidox is now in the preclinical phase; however, research results suggest that cancer patients should have access to Talidox soon.
The Talidox product is developed and produced in the company’s clean room in Marly, Switzerland. One of their first analytical instruments was Izon Science’s qNano. Since last year, researchers at InnoMedica use the qNano to measure the number, size and zeta potential of their liposomes. Unlike dynamic light scattering (DLS), Tunable Resistive Pulse Sensing (TRPS) allows researchers to accurately and simultaneously measure the size and the number of individual liposomes and to provide a real number based distribution. This enables product development and manufacture to be performed with confidence. Pascal Halbherr, InnoMedica’s Production Project Leader said “Getting the qNano into our lab was a turning point and allowed us to be certain about what we were actually producing”.
Related technologies: Nano and micro particle analysis
Brand profile
IZON designs and manufactures precision instrumentation for nano- and micro-scaled particle analysis.
More info at:
www.izon.com